- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07318831
Étude de phase II du Chidamide-Dinutuximab Bêta-Irinotécan-Témozolomide pour le neuroblastome réfractaire/récidivant chez l'enfant
Un essai de phase II du chidamide associé au dinutuximab bêta, à l'irinotécan et au témozolomide pour le neuroblastome réfractaire ou en rechute chez l'enfant
This is a Phase II clinical trial investigating the effectiveness and safety of a four-drug combination-Chidamide, Dinutuximab Beta, Irinotecan, and Temozolomide-for children with relapsed or refractory neuroblastoma. The primary goal is to evaluate how well this regimen works to control the cancer, while the secondary goal is to closely monitor its safety and side effects in these young patients.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Yan Jin
- Numéro de téléphone: +8613212163398
- E-mail: myyaner520@163.com
Lieux d'étude
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chine, 300060
- Recrutement
- Tianjin Medical University Cancer Institute & Hospital
-
Contact:
- Yan Jin, PhD
- Numéro de téléphone: 0086-23340123
- E-mail: jinyan0713@tmu.edu.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 0-18 years at enrolment.
- Histologically diagnosed neuroblastoma defined as high-risk according to the International Neuroblastoma Risk Group classification or Chinese consensus/guideline risk classification.
- Relapsed or refractory neuroblastoma. Relapse is defined as any recurrence of neuroblastoma. Refractory disease is defined as inadequate response to prior therapy, including partial response, minor response or stable disease, followed by progression.
- Prior exposure to histone deacetylase inhibitors, DNA methylation inhibitors or GD2 monoclonal antibodies does not preclude eligibility.
- Presence of evaluable disease.
- Performance status of Lansky score >=50%, Karnofsky score >=50% or ECOG performance status <=3.
- Life expectancy >=12 weeks.
- Adequate bone marrow function: for patients without bone marrow disease, platelet count >=75 x 10^9/L, absolute neutrophil count >=0.75 x 10^9/L and haemoglobin >=8 g/dL with transfusion permitted; for patients with bone marrow disease, platelet count >=50 x 10^9/L, absolute neutrophil count >=0.5 x 10^9/L and haemoglobin >=8 g/dL with transfusion permitted.
- Renal function without clinically significant proteinuria. If urine dipstick protein is >=2+, protein:creatinine ratio must be <0.5 or 24-hour protein excretion must be <0.5 g.
- Serum creatinine <=1.5 x upper limit of normal or calculated glomerular filtration rate >=60 mL/min/1.73 m2 if serum creatinine is higher.
- Adequate liver function: AST or ALT <=2.5 x upper limit of normal and total bilirubin <=1.5 x upper limit of normal; in the presence of hepatic metastases, AST or ALT <=5 x upper limit of normal and total bilirubin <=2.5 x upper limit of normal.
- Cardiac shortening fraction >=29% on echocardiography.
- Coagulation function with INR <=1.5 and APTT <=1.5 x upper limit of normal for age if not receiving anticoagulation; anticoagulation is permitted if INR or APTT is within the therapeutic range and the dose has been stable for at least 2 weeks before registration.
- Oxygen saturation >94% without supplemental oxygen. Ability to comply with the visit schedule and other protocol requirements.
Exclusion Criteria:
- Patients with CTCAE v5.0 Grade 3 or higher toxicities involving hearing impairment, hematologic disorders, hepatic, or renal diseases.
- Patients with CTCAE v5.0 Grade 2 or higher neurotoxicity.
- Major surgical procedure within 14 days prior to the first dose of the study drug.
- Severe infection (requiring IV antibiotics, antifungals, or antivirals) within one week prior to treatment, or unexplained fever >38.5°C during screening or before the first dose.
- Congenital or acquired immunodeficiency, or active infectious diseases such as HIV or active hepatitis (with transaminase levels not meeting inclusion criteria; HBV DNA ≥1000 IU/mL; HCV RNA ≥1000 IU/mL). Chronic HBV carriers with HBV DNA <2000 IU/mL may be enrolled if they receive concurrent antiviral therapy during the trial.
- Any concomitant condition that, in the investigator's judgment, seriously jeopardizes patient safety, may confound the study results, or could impede the patient's completion of the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Chidamide
|
Chidamide (C): 5 mg/10 kg (maximum single dose: 30 mg), administered twice per week. The medication follows a schedule of two weeks on treatment followed by one week off. Specifically, it is taken orally on Days 0, 3, 7, and 10 of each three-week cycle. Chidamide is initiated one day before the start of chemotherapy. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective Response Rate(ORR)
Délai: Baseline and after Cycles 3, 5 or 6, 7 or 8, and 10 (each cycle is 21 days; up to 30 weeks), or earlier if clinically indicated, during treatment and follow-up (up to 5 years).
|
The primary endpoint is defined identically in both sources as the confirmed best overall response of CR or PR per the revised INRC during up to 10 cycles. |
Baseline and after Cycles 3, 5 or 6, 7 or 8, and 10 (each cycle is 21 days; up to 30 weeks), or earlier if clinically indicated, during treatment and follow-up (up to 5 years).
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-Free Survival(PFS)
Délai: From the date of the first dose of study treatment until the date of first documented disease progression or date of death from any cause, whichever occurs first, assessed up to 5 years.
|
From the date of the first dose of study treatment until the date of first documented disease progression or date of death from any cause, whichever occurs first, assessed up to 5 years.
|
|
|
Event-Free Survival(EFS)
Délai: From the date of the first dose of study treatment until the first documented disease progression or relapse per the revised INRC, development of a secondary malignancy, or death from any cause, whichever occurs first, assessed up to 5 years.
|
From the date of the first dose of study treatment until the first documented disease progression or relapse per the revised INRC, development of a secondary malignancy, or death from any cause, whichever occurs first, assessed up to 5 years.
|
|
|
Duration of Response(DOR)
Délai: From the date of first documented complete or partial response per the revised INRC until the date of first documented disease progression or date of death from any cause, whichever occurs first, assessed up to 5 years.
|
From the date of first documented complete or partial response per the revised INRC until the date of first documented disease progression or date of death from any cause, whichever occurs first, assessed up to 5 years.
|
|
|
Overall Survival (OS)
Délai: From the date of the first dose of study treatment until the date of death from any cause, assessed up to 5 years.
|
From the date of the first dose of study treatment until the date of death from any cause, assessed up to 5 years.
|
|
|
Safety assession
Délai: Safety will be assessed from the first dose through 28 days after the last dose or initiation of new anticancer therapy
|
Safety will be assessed from the first dose through 28 days after the last dose or initiation of new anticancer therapy, whichever occurs first, using adverse events, serious adverse events, grade, seriousness, relatedness, dose modifications and treatment discontinuation. |
Safety will be assessed from the first dose through 28 days after the last dose or initiation of new anticancer therapy
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Exploratory endpoints
Délai: Baseline (after enrolment and before the first dose), during treatment (up to 2 years), and at relapse or disease progression.
|
Exploratory endpoints include changes in immune cells and cytokines; transcriptomic assessment of cell state and its association with efficacy and survival; immunohistochemistry, immunocytochemistry or flow cytometry assessment of GD2 expression; assessment of ST8SIA1 and YAP1 expression; exploration of NSE, VMA, LDH and ferritin as biomarkers of efficacy and survival; and monitoring of plasma ctDNA ST8SIA1 methylation before treatment, after treatment and at relapse or progression. |
Baseline (after enrolment and before the first dose), during treatment (up to 2 years), and at relapse or disease progression.
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Tumeurs, neuroépithéliales
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs neuroectodermiques, primitives, périphériques
- Tumeurs neuroectodermiques primitives
- Neuroblastome
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Azoles
- Camptothécine
- Alcaloïdes
- Dacarbazine
- Triazènes
- Imidazoles
- Témozolomide
- Irinotécan
- dinutuximab
Autres numéros d'identification d'étude
- E20251314
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .